These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22447481)

  • 21. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Cheng AY; Leiter LA
    Curr Opin Cardiol; 2006 Jul; 21(4):400-4. PubMed ID: 16755211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.
    Robson J
    Heart; 2008 Oct; 94(10):1331-2. PubMed ID: 18701534
    [No Abstract]   [Full Text] [Related]  

  • 23. Statin treatment for all individuals with cholesterol concentrations above "target"?: "Primum non nocere"--Hippocratic oath.
    Kaski JC
    Cardiovasc Drugs Ther; 2012 Apr; 26(2):189-90. PubMed ID: 22402785
    [No Abstract]   [Full Text] [Related]  

  • 24. Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression.
    Negi S; Ballantyne CM
    J Clin Lipidol; 2010; 4(5):365-70. PubMed ID: 21122680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. US heart doctors defend new prevention guidelines.
    McCarthy M
    BMJ; 2013 Nov; 347():f6957. PubMed ID: 24259332
    [No Abstract]   [Full Text] [Related]  

  • 26. Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence.
    Davidson MH
    J Clin Lipidol; 2010; 4(1):72-3; discussion 74. PubMed ID: 21122630
    [No Abstract]   [Full Text] [Related]  

  • 27. Point: Low-density lipoprotein cholesterol goals in patients with diabetes are not adequately based on evidence.
    Gosmanov AR
    J Clin Lipidol; 2010; 4(1):69-71; discussion 74. PubMed ID: 21122629
    [No Abstract]   [Full Text] [Related]  

  • 28. [The discussion on target goals in lipid reduction is still going on. The Expert Committee--a block for current cardiovascular prevention].
    Olsson AG
    Lakartidningen; 2011 Nov 23-29; 108(47):2442-3. PubMed ID: 22468387
    [No Abstract]   [Full Text] [Related]  

  • 29. Therapy and clinical trials.
    Devendra GP; Krasuski RA
    Curr Opin Lipidol; 2010 Oct; 21(5):471-2. PubMed ID: 20827082
    [No Abstract]   [Full Text] [Related]  

  • 30. [LDL cholesterol in cardiovascular risk patients should be as low as possible].
    MMW Fortschr Med; 2007 Oct; 149(41):44-5. PubMed ID: 17992793
    [No Abstract]   [Full Text] [Related]  

  • 31. [Lipid management--treatment goal and strategy].
    Koshiyama H
    Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The new 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk: comparison with the ESC/EAS recommendations for the management of dyslipidemias].
    Catapano AL; Averna M; Faggiano P; Novo S
    G Ital Cardiol (Rome); 2014 Jan; 15(1):19-20. PubMed ID: 24503730
    [No Abstract]   [Full Text] [Related]  

  • 36. [Guideline for management of lipid metabolism].
    Ishibashi S
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():675-8. PubMed ID: 12387068
    [No Abstract]   [Full Text] [Related]  

  • 37. High-sensitivity C-reactive protein in every chart? The use of biomarkers in individual patients.
    Ben-Yehuda O
    J Am Coll Cardiol; 2007 May; 49(21):2139-41. PubMed ID: 17531664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular disease.
    Ferdinand KC
    Curr Med Res Opin; 2005 Jul; 21(7):1091-7. PubMed ID: 16004678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Statins with a perspective of lifelong therapy].
    Ertaş FS
    Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():29-36. PubMed ID: 19404048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.
    de Lorgeril M; Salen P; Abramson J; Dodin S; Hamazaki T; Kostucki W; Okuyama H; Pavy B; Rabaeus M
    Arch Intern Med; 2010 Jun; 170(12):1032-6. PubMed ID: 20585068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.